Jazz Pharmaceutical to Acquire Cavion for the Expansion of its Sleep and Neurology Portfolio

 Jazz Pharmaceutical to Acquire Cavion for the Expansion of its Sleep and Neurology Portfolio

Jazz Pharmaceuticals Reports Results of JZP-258 in P-III Study for Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepiness

Shots:

  • Jazz acquires Cavion, in all stock transaction making total deal value $312.5M. Cavion to receive $52.5M up front, ~$260M milestones based on certain clinical, regulatory and commercial activities
  • The acquisition will broaden Jazz’s portfolio of sleep and neurological disorders and with the addition of Cavion’s CX-8998 it will further lead to expansion into movement disorders
  • CX-8998 is a modulator of t-type calcium channels and is currently evaluated in P-II trial vs PBO in patients with essential tremor with its expected onset in 2020

Click here to­ read full press release/ article | Ref: Jazz Pharmaceuticals | Image: Behnace

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post